Collegium Pharmaceutical (COLL) Q4 2025 earnings review
Jornay PM Soars, But 2026 Profitability Guidance Disappoints
Collegium delivered a strong finish to 2025, with Q4 product revenues growing 13% YoY to $205.4M, driven by a massive 57% surge in Jornay PM sales. However, despite the top-line beat and excellent cash flow generation ($123M in Q4), the market narrative will likely shift to the remarkably soft 2026 guidance. Management expects 2026 Adjusted EBITDA to be virtually flat (+1% YoY) alongside slowing top-line growth (+4% YoY), signaling that the aggressive investments required to fuel Jornay PM are beginning to severely cap margin expansion.
🐂 Bull Case
The $200M Ironshore acquisition continues to pay massive dividends. Jornay PM achieved record prescriptions (>200K, +16% YoY) and reached an all-time high in prescribers (29K). The drug represents over 20% of total revenue and is guided to grow 31% in 2026.
Collegium generated $329M in operating cash flow in FY25, closed a favorable $980M credit facility, and drove net leverage below 1x. They are perfectly positioned to execute their next strategic acquisition.
🐻 Bear Case
Despite adding ~$45M in high-margin Jornay PM revenue projected for 2026, Adjusted EBITDA is guided to grow by merely ~$5M. The operating leverage investors hoped to see in 2026 is missing.
While overall pain revenues grew 5% YoY, Xtampza ER reversed its growth trend, falling 6% YoY in Q4. If the legacy pain products begin to erode faster than expected, it will drag down the entire company's growth profile.
⚖️ Verdict: ⚪
Neutral. The operational execution on Jornay PM is flawless, and cash generation is superb. However, the tepid 2026 EBITDA guidance implies operating expenses will remain stubbornly high, forcing investors to rely on future, unannounced M&A for the next catalyst.
Key Themes
Jornay PM Commercial Momentum Accelerating
Jornay PM remains the star of the portfolio. Q4 net revenue of $45.9M (+57% YoY) demonstrates the successful integration and expansion of the 180-rep sales force. It is the fastest-growing stimulant for ADHD, commanding a 26% market share in the branded long-acting methylphenidate market, up 6.5 percentage points YoY. The back-to-school season momentum clearly carried through the end of the year.
Profitability Growth Stagnating in 2026
Management previously stated that the impact of Jornay PM investments on adjusted EBITDA margin would improve beginning in 2026. However, the 2026 midpoint guidance for Adjusted EBITDA ($465M) implies just 1% YoY growth compared to 2025's $460.5M, despite a projected $45M top-line increase from Jornay PM. This indicates a deceleration in profit growth and suggests OpEx will remain heavily elevated.
Xtampza ER Reverses Trend
After posting YoY growth earlier in 2025 (e.g., +18% in Q2, +2% in Q3), Xtampza ER experienced a reversal, with Q4 revenue falling 6% YoY to $48.6M. As the second-largest product in the portfolio, any sustained weakness here could jeopardize the 'durable cash cow' narrative surrounding the pain portfolio.
Massive Cash Generation and Refinancing
The company continues to be a cash-generating machine, delivering $123.0M in operating cash flow in Q4 alone ($329.3M for FY25). They successfully closed a new $980M syndicated credit facility to repay their expensive Pharmakon term loan. This move lowers interest costs, extends maturities, and provides significant dry powder ($300M delayed draw, $100M revolver) for future acquisitions.
Defensive Authorized Generic Strategy
Collegium is proactively managing the lifecycle of its Nucynta franchise through an authorized generic (AG) partnership with Hikma. Hikma recently launched the Nucynta AG and will launch the Nucynta ER AG in Q1 2026. While this will cannibalize branded sales, Collegium captures a 'significant share of net profits', cushioning the blow of standard generic erosion.
Other KPIs
GAAP operating expenses surged 37% YoY, primarily reflecting the full-year impact of the expanded Jornay PM sales force and aggressive commercial marketing investments. Adjusted operating expenses (excluding stock-based comp) jumped even higher, up 58% to $237.3M.
Management successfully delivered on their promise to aggressively deleverage. They ended the year with $386.7M in cash, equivalents, and marketable securities, bringing net leverage to below 1x—down dramatically from nearly 2x at the end of 2024.
Guidance
Decelerating. The midpoint implies just 4% YoY growth, a sharp slowdown from the 24% growth achieved in 2025. This suggests the pain portfolio will likely see flat or negative growth, forcing Jornay PM to do all the heavy lifting.
Decelerating, but still robust. The midpoint implies 31% YoY growth. While slower than the 48% growth seen in 2025, it confirms that Jornay PM remains firmly in its hyper-growth adoption phase.
Stable/Decelerating. The midpoint of $465M represents barely a 1% increase over 2025's $460.5M. This contradicts earlier management commentary suggesting EBITDA margins would improve in 2026 as Jornay investments normalized.
Key Questions
EBITDA Margin Disconnect
You previously indicated that the margin drag from Jornay PM investments would begin to alleviate in 2026. With 2026 Adjusted EBITDA guided essentially flat despite $45M in incremental high-margin Jornay revenue, what specific operating expense lines are staying elevated?
Xtampza ER Reversal
Xtampza ER revenue declined 6% YoY in Q4 after growing nicely in earlier quarters. Was this driven by volume weakness, gross-to-net true-ups, or inventory destocking, and what is assumed for this asset in the 2026 revenue guide?
Nucynta AG Economics
With Hikma launching the authorized generics for Nucynta and Nucynta ER, how should we model the gross-to-net and margin profile for the Nucynta franchise in 2026? Does the AG launch explain the conservative 2026 top-line guidance?